Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingjun Zhang

Showing results (381-390 of 386) with videos related to

Pageof 39
Sort By:
You have reached the last page of results.This site can display upto 386 results.
Chemistry & Biology|July 31, 2012
HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoterAlice Kiselyuk, Seung-Hee Lee, Suzette Farber-Katz, et al.
Signal Transduction and Targeted Therapy|September 19, 2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trialJiujie Cui, Shukui Qin, Yuhong Zhou, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFITHuaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.
Pageof 39

Showing results (381-390 of 386) with videos related to

Sort By:
Pageof 39
You have reached the last page of results.This site can display upto 386 results.
Chemistry & Biology|July 31, 2012
HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoterAlice Kiselyuk, Seung-Hee Lee, Suzette Farber-Katz, et al.
Signal Transduction and Targeted Therapy|September 19, 2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trialJiujie Cui, Shukui Qin, Yuhong Zhou, et al.
Experimental Hematology & Oncology|November 22, 2025
Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumorsRongrui Liu, Rongbo Lin, Ning Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFITHuaqiang Zhou, Yuanyuan Zhao, Mingjun Zhang, et al.
JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.
Pageof 39